Investor Relations

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers.

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 2:22 PM ET on Apr 17, 2014
Last Price Change Open Day High 52-Week High
13.52
0.30  down   (2.171%) 13.80 14.44 20.10
Volume Previous Close Day Low 52-Week Low
35,800 13.82 13.37 10.90

View all »   RSSRecent Releases

Mar 24, 2014
Esperion Therapeutics to Present at BioCentury Future Leaders in the Biotech Industry Conference

Mar 5, 2014
Esperion Therapeutics Provides ETC-1002 Program Update; Reports Fourth Quarter and Full Year 2013 Financial Results